Trial Profile
Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- 22 May 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 22 May 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.
- 22 May 2023 Status changed from recruiting to active, no longer recruiting.